Archive for February 2020
Immunexpress Achieves ISO 13485:2016 & EN ISO 13485:2016 Quality Certification for Worldwide Commercialization of SeptiCyte® RAPID
Immunexpress, Pty Ltd & Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced that it has been successfully certified according to ISO 13485:2016 & EN ISO 13485:2016, the international standard for medical device quality management systems. The scope of the certification includes the design and…
Read MoreTapas & Technology with a Live Demo of SeptiCyte® RAPID Test
Join the Immunexpress team for a cocktail reception of Tapas & Technology, during which you can enjoy Spanish Tapas with Rioja wine and watch a demonstration of SeptiCyte™ RAPID running and generating results on the BioCartis Idylla™ platform. There will also be two short presentations. Steven P. LaRosa, MD, Infectious Disease Specialist at Beverly Hospital,…
Read More